Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial;
results newly reported in The Lancet Oncology
- Ziftomenib could be next targeted therapy approved to treat AML
- FDA recognized drug as a ‘breakthrough therapy’ earlier this year
- Results especially promising in patients with high-risk leukemia subtypes
BUFFALO, N.Y. — The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML). The results of the KOMET-001 study, published today in The Lancet Oncology, show that the drug — part of a class of targeted therapies known as menin inhibitors — produced a partial or complete response in about a third of patients, all of whom had received two or more prior therapies.
All 83 patients enrolled in the study experienced disease progression after receiving between 2 and 9 prior therapies. The most pronounced results were seen in patients with NPM1 mutations and KMT2A rearrangements — profiles associated with poorer clinical outcomes…